Positive Conclusion Reached in Immunomodulator I Patent Opposition Patent opposition hearing cancelled
Positive Conclusion Reached in Immunomodulator I Patent Opposition Patent opposition hearing cancelled
Notice of allowance for patent grant in Japan
An important step in the continued protection of Poolbeg’s patent family
Significant progress made and well positioned for future growth
Evgen Pharma PLC (AIM: EVG), renowned for its advancements in sulforaphane-based medicine, recently revamped its board structure.
Evgen Pharma PLC (AIM: EVG) has revealed the conclusive data from its Phase 1b study, which evaluated the new enteric-coated tablet formulation of its primary drug, SFX-01.
Evgen Pharma PLC (AIM: EVG), a clinical-stage pharmaceutical development firm, has disclosed the termination of its patent and knowledge licence agreement with JuvLife Ltd, a subsidiary of Juvenescence Ltd.
Successful Artificial Intelligence led programme identifies multiple influenza drug targets
Next-Generation Oral Vaccine Programme Advancing Through Non-Dilutive Funding
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, confirms that the Company’s